A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) Versus Bupivacaine Alone in Subjects Undergoing Elective Cesarean Section
Phase of Trial: Phase IV
Latest Information Update: 26 May 2018
At a glance
- Drugs Bupivacaine (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Pacira Pharmaceuticals
- 01 May 2018 Planned End Date changed from 1 Jun 2018 to 30 Nov 2018.
- 01 May 2018 Planned primary completion date changed from 1 Feb 2018 to 31 Aug 2018.
- 28 Jul 2017 Status changed from not yet recruiting to recruiting.